D
Solid Biosciences Inc.
SLDB
$2.70
$0.031.12%
D
Sell
1/6/2025Upgraded
Solid Biosciences Inc. (SLDB) was upgraded to D- from E+ on 1/6/2025 due to an increase in the volatility index.
Solid Biosciences Inc. (SLDB) was upgraded to D- from E+ on 1/6/2025 due to an increase in the volatility index.
E
Sell
12/20/2024Downgrade
Solid Biosciences Inc. (SLDB) was downgraded to E+ from D- on 12/20/2024 due to a noticeable decline in the growth index, solvency index and volatility index. Debt to equity increased from 0.01 to 0.02, the quick ratio declined from 12.95 to 7.49, and earnings per share declined from -$0.6125 to -$0.7896.
Solid Biosciences Inc. (SLDB) was downgraded to E+ from D- on 12/20/2024 due to a noticeable decline in the growth index, solvency index and volatility index. Debt to equity increased from 0.01 to 0.02, the quick ratio declined from 12.95 to 7.49, and earnings per share declined from -$0.6125 to -$0.7896.
D
Sell
1/9/2024Upgraded
Solid Biosciences Inc. (SLDB) was upgraded to D- from E+ on 1/9/2024 due to an increase in the solvency index, growth index and volatility index. Operating cash flow increased 34.84% from -$27.47M to -$17.9M, earnings per share increased from -$1.2525 to -$1.05, and EBIT increased 14.09% from -$26.91M to -$23.11M.
Solid Biosciences Inc. (SLDB) was upgraded to D- from E+ on 1/9/2024 due to an increase in the solvency index, growth index and volatility index. Operating cash flow increased 34.84% from -$27.47M to -$17.9M, earnings per share increased from -$1.2525 to -$1.05, and EBIT increased 14.09% from -$26.91M to -$23.11M.
E
Sell
3/16/2023Downgrade
Solid Biosciences Inc. (SLDB) was downgraded to E+ from D- on 3/16/2023 due to a decline in the volatility index.
Solid Biosciences Inc. (SLDB) was downgraded to E+ from D- on 3/16/2023 due to a decline in the volatility index.
D
Sell
3/14/2023Downgrade
Solid Biosciences Inc. (SLDB) was downgraded to D- from D on 03/14/2023.
Solid Biosciences Inc. (SLDB) was downgraded to D- from D on 03/14/2023.
D
Sell
2/9/2023Upgraded
Solid Biosciences Inc. (SLDB) was upgraded to D from E+ on 2/9/2023 due to an increase in the total return index.
Solid Biosciences Inc. (SLDB) was upgraded to D from E+ on 2/9/2023 due to an increase in the total return index.
E
Sell
2/8/2023Downgrade
Solid Biosciences Inc. (SLDB) was downgraded to E+ from D on 2/8/2023 due to a decline in the growth index and solvency index. Operating cash flow declined 28.66% from -$15.88M to -$20.43M.
Solid Biosciences Inc. (SLDB) was downgraded to E+ from D on 2/8/2023 due to a decline in the growth index and solvency index. Operating cash flow declined 28.66% from -$15.88M to -$20.43M.
D
Sell
8/15/2022Upgraded
Solid Biosciences Inc. (SLDB) was upgraded to D from D- on 8/15/2022 due to a large increase in the growth index. Total revenue increased 220.47% from $1.93M to $6.17M, operating cash flow increased 41.6% from -$27.19M to -$15.88M, and EBIT increased 5.95% from -$25.37M to -$23.86M.
Solid Biosciences Inc. (SLDB) was upgraded to D from D- on 8/15/2022 due to a large increase in the growth index. Total revenue increased 220.47% from $1.93M to $6.17M, operating cash flow increased 41.6% from -$27.19M to -$15.88M, and EBIT increased 5.95% from -$25.37M to -$23.86M.
D
Sell
5/16/2022Upgraded
Solid Biosciences Inc. (SLDB) was upgraded to D- from E+ on 05/16/2022.
Solid Biosciences Inc. (SLDB) was upgraded to D- from E+ on 05/16/2022.
E
Sell
5/1/2022Downgrade
Solid Biosciences Inc. (SLDB) was downgraded to E+ from D- on 05/01/2022.
Solid Biosciences Inc. (SLDB) was downgraded to E+ from D- on 05/01/2022.
D
Sell
4/29/2022Downgrade
Solid Biosciences Inc. (SLDB) was downgraded to D- from D on 4/29/2022 due to a decline in the solvency index, growth index and total return index. Total revenue declined 38.97% from $3.15M to $1.93M, earnings per share declined from -$0.1647 to -$0.2249, and EBIT declined 36.03% from -$18.65M to -$25.37M.
Solid Biosciences Inc. (SLDB) was downgraded to D- from D on 4/29/2022 due to a decline in the solvency index, growth index and total return index. Total revenue declined 38.97% from $3.15M to $1.93M, earnings per share declined from -$0.1647 to -$0.2249, and EBIT declined 36.03% from -$18.65M to -$25.37M.
D
Sell
4/21/2022Upgraded
Solid Biosciences Inc. (SLDB) was upgraded to D from E+ on 04/21/2022.
Solid Biosciences Inc. (SLDB) was upgraded to D from E+ on 04/21/2022.
E
Sell
4/20/2022Downgrade
Solid Biosciences Inc. (SLDB) was downgraded to E+ from D on 4/20/2022 due to a large decline in the solvency index and growth index. The quick ratio declined from 10.25 to 8.81, operating cash flow declined 13.3% from -$18.42M to -$20.87M, and total revenue declined 10.83% from $3.54M to $3.15M.
Solid Biosciences Inc. (SLDB) was downgraded to E+ from D on 4/20/2022 due to a large decline in the solvency index and growth index. The quick ratio declined from 10.25 to 8.81, operating cash flow declined 13.3% from -$18.42M to -$20.87M, and total revenue declined 10.83% from $3.54M to $3.15M.
D
Sell
11/9/2021Upgraded
Solid Biosciences Inc. (SLDB) was upgraded to D from E+ on 11/09/2021.
Solid Biosciences Inc. (SLDB) was upgraded to D from E+ on 11/09/2021.
E
Sell
11/8/2021Downgrade
Solid Biosciences Inc. (SLDB) was downgraded to E+ from D on 11/8/2021 due to a decline in the total return index and volatility index.
Solid Biosciences Inc. (SLDB) was downgraded to E+ from D on 11/8/2021 due to a decline in the total return index and volatility index.
D
Sell
11/27/2020Upgraded
Solid Biosciences Inc. (SLDB) was upgraded to D from D- on 11/27/2020 due to an increase in the volatility index and total return index.
Solid Biosciences Inc. (SLDB) was upgraded to D from D- on 11/27/2020 due to an increase in the volatility index and total return index.
D
Sell
11/12/2020Downgrade
Solid Biosciences Inc. (SLDB) was downgraded to D- from D on 11/12/2020 due to a decline in the growth index, valuation index and solvency index. Debt to equity increased from 0.05 to 0.1, the quick ratio declined from 3.07 to 1.68, and operating cash flow declined 19.1% from -$13.07M to -$15.56M.
Solid Biosciences Inc. (SLDB) was downgraded to D- from D on 11/12/2020 due to a decline in the growth index, valuation index and solvency index. Debt to equity increased from 0.05 to 0.1, the quick ratio declined from 3.07 to 1.68, and operating cash flow declined 19.1% from -$13.07M to -$15.56M.
D
Sell
8/7/2020Upgraded
Solid Biosciences Inc. (SLDB) was upgraded to D from D- on 8/7/2020 due to a noticeable increase in the growth index, total return index and volatility index. Operating cash flow increased 55.36% from -$29.27M to -$13.07M, earnings per share increased from -$0.5554 to -$0.3942, and EBIT increased 23.85% from -$24.92M to -$18.97M.
Solid Biosciences Inc. (SLDB) was upgraded to D from D- on 8/7/2020 due to a noticeable increase in the growth index, total return index and volatility index. Operating cash flow increased 55.36% from -$29.27M to -$13.07M, earnings per share increased from -$0.5554 to -$0.3942, and EBIT increased 23.85% from -$24.92M to -$18.97M.
D
Sell
5/8/2020Upgraded
Solid Biosciences Inc. (SLDB) was upgraded to D- from E+ on 5/8/2020 due to a noticeable increase in the growth index and total return index. EBIT increased 22.94% from -$32.33M to -$24.92M, and earnings per share increased from -$0.6641 to -$0.56.
Solid Biosciences Inc. (SLDB) was upgraded to D- from E+ on 5/8/2020 due to a noticeable increase in the growth index and total return index. EBIT increased 22.94% from -$32.33M to -$24.92M, and earnings per share increased from -$0.6641 to -$0.56.
E
Sell
3/16/2020Downgrade
Solid Biosciences Inc. (SLDB) was downgraded to E+ from D- on 3/16/2020 due to a major decline in the total return index, growth index and volatility index. Operating cash flow declined 10.42% from -$19.24M to -$21.25M, and EBIT declined 8.79% from -$29.72M to -$32.33M.
Solid Biosciences Inc. (SLDB) was downgraded to E+ from D- on 3/16/2020 due to a major decline in the total return index, growth index and volatility index. Operating cash flow declined 10.42% from -$19.24M to -$21.25M, and EBIT declined 8.79% from -$29.72M to -$32.33M.
D
Sell
11/14/2018Upgraded
Solid Biosciences Inc. (SLDB) was upgraded to D- from E- on 11/14/2018 due to a large increase in the total return index.
Solid Biosciences Inc. (SLDB) was upgraded to D- from E- on 11/14/2018 due to a large increase in the total return index.
E
Sell
5/14/2018None
Solid Biosciences Inc. (SLDB) was downgraded to E- from U on 05/14/2018.
Solid Biosciences Inc. (SLDB) was downgraded to E- from U on 05/14/2018.
NASDAQ
04/11/2025 4:00PM Eastern
Quotes delayed
